1. |
Malkovska V, Sondel PM, Malkovsky M. Tumor immunotherapy 〔J〕. Curr Opin Immunol, 1989; 1(2)∶883.
|
2. |
Rosenberg SA, Michael T, Lotze MT, et al. A progrom report on the treatment of 157 patients with advanced cancer using lymphokineactived killer cells and IL2 alone 〔J〕. N Engl J Med, 1987; 316(5)∶889.
|
3. |
Forni G, Cavallo GP, Giovarelli M, et al. Tumor immunotherapy by local injection of IL2 and nonreactive lymphocytes. Experimental and clinical results 〔J〕. Prog Exp Tumor Res, 1988; 32(1)∶187.
|
4. |
Rosenberg SA, Power LB, Noonan KE, et al. Gene transfer into human immunotherapy of patient with advanced meianoma using tumor TIL modified by retroviral gene transduction 〔J〕. N Engl J Med, 1990; 323(10)∶570.
|
5. |
Anderson C. Gene therapy research under fire over controversial cancer trail 〔J〕.Nature, 1992; 360(6403)∶399.
|
6. |
Rosenberg SA, Puyal C, Felgner PL, et al. The immunotherapy and gene therapy of cancer 〔J〕. J Clin Oncol, 1992; 10(2)∶180.
|
7. |
Roth SA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going 〔J〕? J Nat Can Inst, 1997; 89(1)∶21.
|
8. |
Guenther G, Connid F, Anna G, et al. Retroviral vectormediated lymphokine gene transfer into human renal cancer cells 〔J〕. Cancer Research, 1992; 52(22)∶6229.
|
9. |
Thara H, Sandgren EP, Quaife CJ, et al. Antitumor effects of IL12: application for the immunotherapy and gene therapy of cancer 〔J〕. Ther Gene, 1995; 2(2)∶96.
|
10. |
Miller AR, Reters WT, Posner M, et al. Cytokine mediated gene therapy for cancer 〔J〕. Am Surg Oncol, 1994; 1(5)∶436.
|
11. |
Sobol RE, Dinman JD, Icho T, et al. IL2 gene therapy in a patient with glioblastoma 〔J〕. Gene Ther, 1995; 2(2)∶164.
|
12. |
Hui K, Grosveld F, Festenstein H, et al. Rejective of transplantable AKP leukaemia cells following MHC DNAmediated cell transformation 〔J〕. Nature, 1984; 311(6010)∶750.
|
13. |
James RF, Edwards S, Hui RM, et al. The effect of class 2 gene transfection on the tumorigenicity of the H2knegative mouse leukaemia cell line K36.16 〔J〕. Immunology, 1991; 72(2)∶213.
|
14. |
Nabel GJ, Nabel EJ, Yang ZY, et al. Direct gene transfer with DNAlipsome complex in melanoma: expression, biologic activity, and lack of toxicity in humans 〔J〕. Proc Natl Acad Sci USA, 1993; 90(6)∶11306.
|
15. |
Sanda MG, Restifo NP, Walsh JC, et al. Molecular characterization of defective antigen processing in human prostate cancer 〔J〕. J Natl Cancer Inst, 1995; 87(1)∶280.
|
16. |
Schwann RN. Costimulation of T lymphocytes: the role of CD28, CTL4 and B7/BB1 in IL2 production and immunotherapy 〔J〕. Cell, 1992; 71(7)∶1065.
|
17. |
Chen L. Manipulation of T cell response to tumor by targeting on costimnlatory pathway 〔J〕. Leukemia, 1997; 11(3)∶567.
|
18. |
Geldhof AB, Geert R, Marleen B, et al. Expression of B71 Highly metastatic mouse T lymphomas induces optimol natural killer cellmediated cytotoxicity 〔J〕. Cancer Res, 1995; 55(13)∶2730.
|
19. |
Fenton RT, Bate SE, Sonnevel T, et al. A phase I trial of B7transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cellmediated immunity against tumorassociated antigen presented by HLA A2 or HLAA1 in patients with stage IV melanoma 〔J〕. Human Gene Therapy, 1995; 6(1)∶87.
|
20. |
Patel RL, Andre L, Richard D, et al. Cancer gene therapy annual conference 1997 〔J〕. Human Gene Therapy, 1998; 9(2)∶283.
|
21. |
Chen L, Thomas EK, Hus L, et al. Human papilloma virus type 16 nucleoprotien E7 is a tumor rejection antigen 〔J〕. Proc Natl Ad Sci USA, 1991; 88(1)∶110.
|
22. |
王洪平, 吴易元. CD1: 第三类抗原递呈分子 〔J〕. 国外医学分子生物学分册, 1997; 19(2)∶75.
|
23. |
DiMaio JM, Clary BM, Via DF, et al . Directed enzyme prodrug gene therapy for pantreatic cancer in vivo 〔J〕. Surgery, 1994; 116(2)∶205.
|
24. |
Thomas F, Gajewski R, Jean C,et al. Costimulation with B71, IL6, and IL12 is sufficient for primary generation of murine antitumor cytotoxic T lymphocytes in vivo 〔J〕. J Immunnol, 1995; 154(11)∶5637.
|